Fig. 3

YAP positively regulated the expression of LOXL2 at the transcriptional level. A Schematic structure of the full-length LOXL2 promoter-reporter and its deletion-mutant constructs. Three potential YAP binding sites are indicated. B, C LOXL2 promoter activity in 293T and LX-2 cells at 48 h after transfection with pcDNA3.1-YAP (pYAP) and pcDNA3.1 (p3.1), pcDNA3.1-LOXL2 vector (pLOXL2) (n = 3; *p < .05, **p < .01, ***p < .001, and n.s., Not significant). D LOXL2 promoter activity in LX-2 cells cotransfected with pLOXL2-907 promoter construct and different doses of pYAP or p3.1 vector (n = 3; **p < .01). E LOXL2 promoter activity in LX-2 cells cotransfected with pLOXL2-907 promoter construct and different doses of YAP shRNA (sh-YAP) or control shRNA (sh-Ctr) vector (n = 4; **p < .01, ***p < .001). F, G. ChIP-qPCR analysis of YAP binding to the LOXL2 promoter region with potential YAP binding site in 293T or LX-2 cells with Ad-GFP or Ad-YAP transfection (n = 4; **p < .01, ***p < .001, and ^###p < .001). The cell lysate was precipitated with an anti-IgG or anti-YAP antibody. qPCR with primers containing site 1 (− 895 to − 887) was used to identify the YAP binding